IQ-AI Limited said its Gallium Maltolate phase I clinical trial has been rescheduled for the fourth quarter rather than the summer as planned after a change to the trial agent's encapsulation supplier.
“While the selection and qualification process will result in a delay, securing and establishing a robust supply chain now will benefit subsequent trial phases and support high-volume production capacity,” investors were told.
“Overall, the trial continues to advance at a remarkable pace and has obtained all regulatory and institutional milestones as scheduled.”
The study will assess the potential of Gallium Maltolate to treat Glioblastoma Multiforme, the most common brain tumour.
Early success would see IQ-AI apply for orphan drug status for its discovery, a process in the US that provides certain protections and can also potentially fast-track approval.